RudaCure CEO Yongho Kim and BD team member Harris Hasrol participated in the 犹他大学 technology briefing held from September 25 to 29, where they promoted the company's technologies to 美国-based 风险资本ists and conducted investment meetings.
According to their report, there was strong interest from local attendees in the 慢性疼痛治疗药, as well as significant attention toward the 干眼症治疗药 and 角膜损伤恢复 agent currently in clinical preparation. The reception indicated an active desire to move forward with 联合研究 and investment opportunities.
It is expected that the investor presentation taking place in 旧金山 from October 2nd onward will also yield positive results.
Following the 旧金山 investor presentation, BD team member Harris Hasrol will travel to 新加坡 to attend the 新韩Square Bridge-organized investor roadshow (October 10–13), where he will present the company's technologies to Asian investors. He will then travel to 欧洲 to attend Bio 欧洲, where he plans to discuss specific details of 技术转让 with Ceva, with whom RudaCure is currently in discussions regarding 兽用 药物开发.